Pharmacogenetics of irinotecan metabolism and transport: An update

详细信息    查看全文

• 作者：Nicola F. Smith ; William D. Figg and Alex Sparreboom
• 关键词：CPT-11 ; SN-38 ; CYP3A ; CES ; UGT1A ; ABCB1 ; ABCC1 ; ABCC2 ; ABCG2
• 刊名：Toxicology in Vitro
• 出版年：2006
• 出版时间：March 2006
• 年：2006
• 卷：20
• 期：2
• 页码：163-175
• 全文大小：240 K

文摘

The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100 to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are extremely complex and have been the subject of intensive investigation in recent years. Irinotecan is subject to extensive metabolism by various polymorphic enzymes, including CES2 to form SN-38, members of the UGT1A subfamily, and CYP3A4 and CYP3A5, which form several pharmacologically inactive oxidation products. Elimination of irinotecan is also dependent on drug-transporting proteins, notably ABCB1 (P-glycoprotein), ABCC2 (cMOAT) and ABCG2 (BCRP), present on the bile canalicular membrane. The various processes mediating drug elimination, either through metabolic breakdown or excretion, likely impact substantially on interindividual variability in drug handling. This report provides an update on current strategies to individualize irinotecan chemotherapy based on each patient’s genetic constitution, which may ultimately lead to more selective use of this agent.